Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus (TRED)
Comparison Of Two Triple Hypoglycemic Regimens In Achieving Glycemic Control And Diabetes Remission In Hospitalized Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Multicenter, Randomized, Clinical Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Wangen Li, Dr
- Phone Number: 86-20-34152032
- Email: liwg660@126.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510260
- Recruiting
- The Second Affiliated Hospital, Guangzhou Medical University
-
Contact:
- Wangen Li, Dr
- Phone Number: 86-20-34152032
- Email: liwg660@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with newly diagnosed type 2 diabetes.
- Age between 18 and 65 years old.
- HbA1c ≥ 9.0%.
Exclusion Criteria:
- Type 1 diabetes.
- Elevated creatinine or urinary albumin/creatinine.
- Combined with coronary heart disease, tumor or pregnancy.
- Receiving glucocorticoids.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Semaglutide group: patients receive semaglutide treatment.
Patients receive 0.25 mg per week in the first month, 0.5 mg per week in the second month, and 1.0mg of semaglutide per week from the 3rd to the 8th month.
|
0.25 mg per week in the first month, 0.5 mg per week in the second month, and 1.0mg of semaglutide per week from the 3rd to the 8th month.
|
|
Active Comparator: Oral medication group: patients receive triple hypoglycemic oral medications.
Patients in oral medication group received sitagliptin 0.1g per day.
Both groups were simultaneously treated with metformin (1.0g daily, divided into two doses) and empagliflozin (10mg daily).
|
Sitagliptin 0.1g per day.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Diabetes remission rate
Time Frame: From enrollment to the end of follow-up at 11 months
|
From enrollment to the end of follow-up at 11 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
HbA1c
Time Frame: From enrollment to the end of follow-up at 11 months
|
From enrollment to the end of follow-up at 11 months
|
|
Hypoglycemia rate
Time Frame: From enrollment to the end of follow-up at 11 months
|
From enrollment to the end of follow-up at 11 months
|
|
Adverse reactions
Time Frame: From enrollment to the end of follow-up at 11 months
|
From enrollment to the end of follow-up at 11 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Metabolic Diseases
- Glucose Metabolism Disorders
- Nutritional and Metabolic Diseases
- Diabetes Mellitus, Type 2
- Diabetes Mellitus
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hypoglycemic Agents
- Protease Inhibitors
- Enzyme Inhibitors
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Azoles
- Pharmacologic Actions
- Chemical Actions and Uses
- Pyrazines
- Triazoles
- Sitagliptin Phosphate
- Dipeptidyl-Peptidase IV Inhibitors
- semaglutide
Other Study ID Numbers
Other Study ID Numbers
- TRED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.